Our pursuit of groundbreaking research in endocrinology, diabetes and metabolism complements our division’s commitment to excellence in clinical care and education.
Our translational research programs contribute to major advances in the treatment and prevention of diabetes and an array of metabolic diseases, including obesity.
Our division was the first to describe the anti-inflammatory effect of insulin, the pro-inflammatory effects of macronutrients, the high prevalence of hypogonadism and its contribution to insulin resistance in males with type 2 diabetes and the use of GLP-1 agonists in type 1 diabetes.
Numerous trials funded by NIH, ADA, JDRF, and the pharmaceutical industry based on these themes have been completed and are ongoing in the department.
Approximately 300 peer reviewed manuscripts have been publish in the last 30 years.